JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• TMS for Post Stroke Depression

  NCT04093843

  Condition:   Post-stroke Depression
  Intervention:   Device: TMS
  Sponsor:   Amelia Adcock
  Recruiting
• Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes

  NCT03968809

  Condition:   Coronary Artery Disease
  Intervention:   Diagnostic Test: CardioFlux Magnetocardiography
  Sponsor:   Genetesis Inc.
  Recruiting
• Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells

  NCT03861598

  Conditions:   Glioblastoma Multiforme;   Glioblastoma
  Intervention:   Drug: Carvedilol
  Sponsors:   West Virginia University;   West Virginia Clinical and Translational Science Institute
  Recruiting
• Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

  NCT03716193

  Conditions:   Skin Lesion;   Skin Cancer;   Skin Melanoma;   Tumor Skin
  Intervention:   Other: Oxygen
  Sponsors:   West Virginia University;   West Virginia Clinical and Translational Science Institute;   Mary Babb Randolph Cancer Center at West Virginia University Hospitals
  Recruiting
• Use of Tele-Exercise for Translating an Evidence-Based Fall-Prevention Program for Older Adults in West Virginia

  NCT03714100

  Condition:   Accidental Falls
  Intervention:   Behavioral: Tai Ji Quan: Moving for Better Balance
  Sponsor:   West Virginia University
  Recruiting
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612

  Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Dedifferentiated Carcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Dedifferentiated Carcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

  NCT02972840

  Condition:   Lymphoma, Mantle Cell
  Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
  Sponsor:   Acerta Pharma BV
  Recruiting
• Symptom Management Implementation of Patient Reported Outcomes in Oncology

  NCT03850912

  Conditions:   Other Cancer;   Gastrointestinal Cancer;   Thoracic Cancer;   Gynecologic Cancer
  Interventions:   Other: eSyM App Usage;   Other: SASS Questionnaire
  Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   RTI International;   Baptist Memorial Health Care Corporation;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   West Virginia University;   Lifespan
  Recruiting
• Longitudinal Performance of Epi proColon

  NCT03218423

  Conditions:   Colorectal Cancer;   Colorectal Neoplasms
  Intervention:   Device: Epi proColon
  Sponsor:   Epigenomics, Inc
  Recruiting
• A Phase 2a Diabetic Kidney Disease Study

  NCT04170543

  Condition:   Diabetic Kidney Disease
  Interventions:   Drug: MEDI3506;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

  NCT04129619

  Condition:   Irritable Bowel Syndrome With Diarrhea
  Interventions:   Drug: ORP-101;   Drug: Placebo
  Sponsors:   OrphoMed, Inc.;   PPD
  Recruiting
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688

  Condition:   Colorectal Adenocarcinoma
  Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

  NCT04085367

  Condition:   Actinic Keratoses
  Intervention:   Drug: MAL 16.8% cream
  Sponsor:   Galderma R&D
  Recruiting
• Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665

  Conditions:   Atrial Fibrillation;   Stroke;   Bleeding
  Interventions:   Drug: Antiplatelet-only strategy;   Drug: Oral Anticoagulant plus background antiplatelet therapy
  Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Vanderbilt University Medical Center
  Recruiting
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

  NCT03953079

  Condition:   Neovascular Age-Related Macular Degeneration
  Interventions:   Drug: Drug: GB-102;   Drug: Aflibercept
  Sponsor:   Graybug Vision
  Recruiting
• Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619

  Condition:   ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
  Intervention:   Device: Impella CP® placement prior to reperfusion with Primary PCI
  Sponsor:   Abiomed Inc.
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• OTO-313 in Subjects With Subjective Tinnitus

  NCT03918109

  Condition:   Tinnitus, Subjective
  Interventions:   Drug: OTO-313;   Drug: Placebo
  Sponsor:   Otonomy, Inc.
  Recruiting
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693

  Condition:   Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
  Interventions:   Drug: FDC macitentan/tadalafil;   Drug: Macitentan 10 mg;   Drug: Tadalafil 40 mg;   Drug: Placebo FDC;   Drug: Placebo macitentan;   Drug: Placebo tadalafil
  Sponsors:   Actelion;   Covance;   Almac Clinical Technologies;   WorldCare Clinical;   Frontier Science Foundation
  Recruiting
• To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020

  Conditions:   Dry Age-related Macular Degeneration;   Macular Degeneration;   Retinal Disease;   Retinal Degeneration;   Geographic Atrophy;   Macular Atrophy
  Intervention:  
  Sponsor:   Gyroscope Therapeutics
  Recruiting
• A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL

  NCT03467373

  Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
  Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Gilteritinib;   Drug: Midostaurin;   Drug: Daunorubicin;   Drug: Cytarabine
  Sponsors:   PrECOG, LLC.;   Astellas Pharma Inc
  Recruiting
• Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

  NCT03833154

  Condition:   Carcinoma, Non-Small-Cell Lung
  Interventions:   Drug: Durvalumab;   Other: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319

  Condition:   Nonsquamous Non-small Cell Lung Cancer
  Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Lenvatinib;   Drug: Placebo matching lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

  NCT03822351

  Conditions:   Stage III Non-small Cell Lung Cancer;   Unresectable
  Interventions:   Drug: Durvalumab + Oleclumab;   Drug: Durvalumab;   Drug: Durvalumab + Monalizumab
  Sponsor:   MedImmune LLC
  Recruiting
• A Disease Registry of Patients With Mantle Cell Lymphoma

  NCT03816683

  Condition:   Mantle Cell Lymphoma
  Intervention:  
  Sponsor:   AstraZeneca
  Recruiting
• Sleep for Stroke Management and Recovery Trial

  NCT03812653

  Conditions:   Ischemic Stroke;   Sleep Apnea;   Sleep Apnea, Obstructive;   TIA;   Stroke;   CPAP;   Telemedicine;   Home Sleep Apnea Test;   Randomized Clinical Trial;   Multicenter Trial
  Intervention:   Device: CPAP
  Sponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   FusionHealth LLC;   Medical University of South Carolina;   University of Cincinnati
  Recruiting
• Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer

  NCT03801902

  Conditions:   Locally Advanced Lung Non-Small Cell Carcinoma;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
  Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Durvalumab;   Other: Placebo;   Drug: Carboplatin/Paclitaxel;   Drug: Cisplatin/Gemcitabine;   Drug: Pemetrexed/Cisplatin;   Drug: Pemetrexed/Carboplatin
  Sponsor:   AstraZeneca
  Recruiting
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957

  Condition:   Hepatocellular Carcinoma
  Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Other: Placebo;   Procedure: Transarterial Chemoembolization (TACE)
  Sponsor:   AstraZeneca
  Recruiting
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

  NCT03777436

  Condition:   Psoriasis
  Interventions:   Drug: Apremilast;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• SCS Research Study

  NCT03763708

  Conditions:   Limb Pain;   Trunk Pain
  Intervention:   Device: Spinal Cord Stimulation
  Sponsor:   MedtronicNeuro
  Recruiting
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

  NCT03737851

  Condition:   Multiple Sclerosis (MS)
  Interventions:   Drug: elezanumab;   Drug: placebo
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

  NCT03737812

  Condition:   Multiple Sclerosis (MS)
  Interventions:   Drug: elezanumab;   Drug: placebo
  Sponsor:   AbbVie
  Recruiting
• Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979

  Condition:   Acute Ischemic Stroke
  Interventions:   Drug: Argatroban;   Drug: Eptifibatide;   Drug: Placebo
  Sponsors:   University of Cincinnati;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

  NCT03732794

  Conditions:   Atrial Fibrillation;   Persistent Atrial Fibrillation;   Longstanding Persistent Atrial Fibrillation
  Intervention:   Device: AtriCure CryoICE & AtriClip LAA Exclusion
  Sponsor:   AtriCure, Inc.
  Recruiting
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

  NCT03721172

  Condition:   Psoriasis
  Interventions:   Drug: Apremilast;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

  NCT03716505

  Condition:   Migraine Disorders
  Interventions:   Device: gammaCore Sapphire active;   Device: gammaCore Sapphire Sham
  Sponsor:   ElectroCore INC
  Recruiting
• Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

  NCT03712345

  Conditions:   Granulomatosis With Polyangiitis (GPA);   Microscopic Polyangiitis (MPA)
  Interventions:   Drug: IFX-1;   Drug: Placebo
  Sponsors:   InflaRx GmbH;   Iqvia Pty Ltd
  Recruiting
• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

  NCT03711929

  Condition:   Non Infectious Uveitis
  Interventions:   Drug: DE-109 Intravitreal Injections;   Other: Sham Procedure
  Sponsor:   Santen Inc.
  Recruiting
• ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

  NCT03689712

  Condition:   Oral Mucositis
  Interventions:   Drug: GC4419;   Drug: Placebo
  Sponsor:   Galera Therapeutics, Inc.
  Recruiting
• Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

  NCT03664674

  Condition:   Meniere Disease
  Interventions:   Drug: OTO-104;   Drug: Placebo
  Sponsor:   Otonomy, Inc.
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

  NCT03656536

  Conditions:   Unresectable Cholangiocarcinoma;   Metastatic Cholangiocarcinoma
  Interventions:   Drug: Pemigatinib;   Drug: Gemcitabine;   Drug: Cisplatin
  Sponsor:   Incyte Corporation
  Recruiting
• Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

  NCT03628066

  Condition:   Breast Cancer
  Interventions:   Drug: Letrozole;   Drug: Palbociclib;   Drug: Goserelin;   Diagnostic Test: Oncotype DX Breast Recurrence Score
  Sponsors:   NSABP Foundation Inc;   Genomic Health®, Inc.;   Pfizer
  Recruiting
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  NCT03619213

  Condition:   Heart Failure With Preserved Ejection Fraction
  Interventions:   Drug: Dapagliflozin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema

  NCT03610646

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: MYL-1701P;   Drug: Eylea
  Sponsors:   Mylan Inc.;   Momenta Pharmaceuticals, Inc.
  Recruiting
• Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

  NCT03607838

  Condition:   Lumbar Disc Herniation
  Interventions:   Drug: SI-6603;   Drug: Sham injection
  Sponsor:   Seikagaku Corporation
  Recruiting
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

  NCT03599713

  Condition:   Metastatic Merkel Cell Carcinoma
  Intervention:   Drug: INCMGA00012
  Sponsor:   Incyte Corporation
  Recruiting
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

  NCT03587805

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Tralokinumab
  Sponsor:   LEO Pharma
  Recruiting
• Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

  NCT03540160

  Conditions:   Pruritus;   Prurigo Nodularis;   Atopic Dermatitis;   Psoriasis
  Intervention:   Drug: 5 mg Serlopitant Tablets
  Sponsor:   Menlo Therapeutics Inc.
  Recruiting
• Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

  NCT03521934

  Condition:   Heart Failure-Type 2 Diabetes Mellitus
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

  NCT03488693

  Condition:   Breast Cancer
  Interventions:   Radiation: Radiation;   Other: No Radiation
  Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
  Recruiting
• A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

  NCT03445533

  Condition:   Metastatic Melanoma
  Interventions:   Drug: Ipilimumab;   Drug: IMO-2125
  Sponsors:   Idera Pharmaceuticals, Inc.;   Bristol-Myers Squibb
  Recruiting
• Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

  NCT03433274

  Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Insufficiency;   Cardiovascular Diseases;   Valve Disease, Heart;   Heart Valve Diseases;   Functional Mitral Regurgitation;   Degenerative Mitral Valve Disease
  Interventions:   Device: Tendyne Mitral Valve System;   Device: MitraClip System
  Sponsor:   Abbott Medical Devices
  Recruiting
• Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

  NCT03417388

  Condition:   Coronary Artery Disease
  Interventions:   Drug: High dose potent statin;   Drug: ACE-I (lisinopril) or ARB (losartan);   Drug: Aspirin;   Behavioral: Lifestyle Counseling;   Behavioral: Quality of Life Questionnaires
  Sponsors:   University of Florida;   United States Department of Defense
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

  NCT03383146

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491

  Condition:   Pancreas Adenocarcinoma
  Interventions:   Device: NovoTTF-100L(P);   Drug: Gemcitabine;   Drug: nab paclitaxel
  Sponsor:   NovoCure Ltd.
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702

  Condition:   Stage II Prostate Adenocarcinoma
  Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

  NCT03354273

  Condition:   Coronary Artery Disease (CAD)
  Interventions:   Drug: PET MPI;   Drug: SPECT MPI;   Drug: Pharmacological stress agents
  Sponsors:   GE Healthcare;   Pharmaceutical Product Development, LLC
  Recruiting
• A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)

  NCT03347188

  Condition:   Post-Traumatic Headache
  Interventions:   Drug: Fremanezumab;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

  NCT03323151

  Condition:   Mantle-Cell Lymphoma
  Interventions:   Drug: Ixazomib;   Drug: Ibrutinib
  Sponsors:   PrECOG, LLC.;   Takeda
  Recruiting
• SHERLOCK 3CG™ Diamond Tip Confirmation System

  NCT03288766

  Conditions:   Indication for Peripheral Intravenous Catheterization;   Atrial Flutter;   Premature Atrial Contraction;   Premature Ventricular Contraction;   Premature Junctional Contraction;   Tachycardia;   Atrioventricular Block;   Bundle-Branch Block
  Intervention:   Procedure: PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
  Sponsor:   C. R. Bard
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

  NCT03285308

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554

  Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

  NCT03233191

  Condition:   Breast Screening
  Interventions:   Procedure: Digital Mammography;   Procedure: Digital Tomosynthesis Mammography;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI);   Canadian Cancer Trials Group (CCTG)
  Recruiting
• Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

  NCT03199885

  Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  NCT03175224

  Conditions:   Solid Tumor;   Advanced Cancer;   Renal Cancer;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   NSCLC;   Lung Cancer
  Intervention:   Drug: APL-101 Oral Capsules
  Sponsor:   Apollomics Inc.
  Recruiting
• Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771

  Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

  NCT03105102

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab SC;   Drug: risankizumab IV;   Drug: placebo for risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

  NCT03070886

  Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

  NCT02997228

  Conditions:   Metastatic Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

  NCT02997202

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: gilteritinib;   Drug: Placebo
  Sponsors:   Astellas Pharma Global Development, Inc.;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network
  Recruiting
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347

  Condition:   Treatment Naive Follicular Lymphoma
  Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
  Sponsor:   Pharmacyclics LLC.
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• NBP in Adult Patients With Acute Ischemic Stroke (AIS)

  NCT02905565

  Condition:   AIS
  Interventions:   Drug: NBP Softgel Capsules;   Drug: Placebo
  Sponsor:   CSPC-NBP Pharmaceutical Co., Ltd.
  Recruiting
• Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

  NCT02820363

  Condition:   Tibial Fracture
  Interventions:   Device: CERAMENT|G;   Procedure: SOC treatment
  Sponsor:   BONESUPPORT AB
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

  NCT02715284

  Condition:   Advanced or Metastatic Solid Tumors
  Intervention:   Biological: dostarlimab
  Sponsor:   Tesaro, Inc.
  Recruiting
• Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

  NCT02680184

  Condition:   Melanoma
  Interventions:   Drug: CMP-001;   Drug: Pembrolizumab
  Sponsor:   Checkmate Pharmaceuticals
  Recruiting
• Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

  NCT02507687

  Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
  Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
  Sponsor:   Allergan
  Recruiting
• RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

  NCT02489903

  Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
  Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
  Sponsor:   EpicentRx, Inc.
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

  NCT02364557

  Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
  Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Expanded Clinical Study of the Tendyne Mitral Valve System

  NCT02321514

  Condition:   Mitral Valve Regurgitation
  Intervention:   Device: Tendyne Mitral Valve System
  Sponsor:   Abbott Medical Devices
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)

  NCT02016781

  Condition:   MDS
  Interventions:   Procedure: Allogeneic Hematopoietic Cell Transplant;   Procedure: Hypomethylating Therapy / Best Supportive Care
  Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
  Recruiting
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

  NCT01996865

  Condition:   Lymphoma, Non-Hodgkin
  Interventions:   Drug: Lenalidomide;   Drug: Rituximab
  Sponsor:   Celgene
  Recruiting
• A Safety Study of SGN-LIV1A in Breast Cancer Patients

  NCT01969643

  Condition:   Breast Cancer
  Interventions:   Drug: SGN-LIV1A;   Drug: Trastuzumab
  Sponsor:   Seattle Genetics, Inc.
  Recruiting
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999

  Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• Connect® MDS/AML Disease Registry

  NCT01688011

  Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
  Intervention:  
  Sponsor:   Celgene
  Recruiting
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

  NCT00887146

  Condition:   Brain and Central Nervous System Tumors
  Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
  Recruiting
• Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

  NCT04101721

  Condition:   Retinopathy of Prematurity
  Interventions:   Drug: aflibercept;   Procedure: laser photocoagulation
  Sponsor:   Regeneron Pharmaceuticals
  Recruiting
• The Global cVAD Study

  NCT04136392

  Condition:   Cardiovascular Diseases
  Intervention:   Device: ABIOMED, Inc. hemodynamic support devices
  Sponsors:   Abiomed Inc.;   Beth Israel Deaconess Medical Center;   Yale University
  Recruiting
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866

  Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045

  Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
  Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
  Sponsor:   LivaNova
  Recruiting
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03493685

  Condition:   Focal Segmental Glomerulosclerosis
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

  NCT03290781

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Ontamalimab;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085

  Conditions:   Crohn's Disease;   Ulcerative Colitis
  Interventions:   Drug: 25 mg Ontamalimab;   Drug: 75 mg Ontamalimab
  Sponsor:   Shire
  Recruiting
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

  NCT03259334

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Ontamalimab;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

  NCT03181932

  Conditions:   MRSA;   Cystic Fibrosis
  Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
  Sponsor:   Savara Inc.
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

  NCT02815891

  Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431

  Condition:   Solid Tumors Harboring NTRK Fusion
  Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
  Sponsor:   Bayer
  Recruiting
• Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

  NCT01652157

  Condition:   Fibrosing Colonopathy
  Interventions:   Biological: ULTRESA;   Biological: PANCREAZE;   Biological: CREON;   Biological: ZENPEP;   Biological: other non-sponsor pancreatic enzyme replacement therapy;   Biological: PERTZYE;   Other: No pancreatic enzyme replacement therapy
  Sponsors:   AbbVie;   Cystic Fibrosis Foundation;   Digestive Care, Inc.;   Forest Research Institute, Inc., an affiliate of Actavis, Inc.;   VIVUS, Inc.
  Recruiting
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  NCT01351545

  Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
  Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
  Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Condition:   Childhood Malignant Neoplasm
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting